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Abstract
Purpose—Although previous studies demonstrate associations between adverse perinatal 
outcomes and developmental disabilities (DDs), study of population impacts is limited.
Methods—We computed relative risks adjusted (aRRs) for sociodemographic factors and 
component and summary population attributable fractions (PAFs) for associations between very 
low birth weight (VLBW, all preterm births), moderately low birth weight (MLBW) + Preterm, 
MLBW at term, and normal birth weight (NBW) + Preterm and seven DDs (cerebral palsy [CP], 
autism spectrum disorder [ASD], intellectual disability [ID], behavioral-conduct disorders, 
attention-deficit-hyperactivity disorder [ADHD], learning disability [LD], and other 
developmental delay) among children aged 3–17 years in the 2011–2012 National Survey of 
Children’s Health.
Results—VLBW-Preterm, MLBW-Preterm and NBW-Preterm were strongly to moderately 
associated with CP (aRRs: 43.5, 10.1, and 2.2, respectively; all significant) and also associated 
with ID, ASD, LD, and other developmental delay (aRR ranges: VLBW-Preterm 2.8–5.3; MLBW-
Preterm 1.9–2.8; and NBW-Preterm 1.6–2.3). Summary PAFs for preterm birth and/or LBW were 
55% for CP, 10%–20% for ASD, ID, LD, and other developmental delay, and less than 5% for 
ADHD and behavioral-conduct disorders. Findings were similar whether we assessed DDs as 
independent outcomes or within mutually exclusive categories accounting for DD co-occurrence.
Conclusions—Preterm birth has a sizable impact on child neurodevelopment. However, relative 
associations and population impacts vary widely by DD type.
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Introduction
Developmental disabilities (DDs) are chronic conditions associated with significant 
impairments in physical, cognitive, behavioral, and/or speech/language functioning. The 
prevalence of DDs in US children is estimated at 15% overall [1] and ranges from less than 
1% (e.g., cerebral palsy [CP]) [2] to 9% (e.g., attention-deficit-hyperactivity disorder 
[ADHD]) [3]. In addition to functional limitations, children with DDs have increased 
prevalence of many health conditions including asthma, eczema, gastrointestinal disorders, 
and obesity [4,5]. Although the causes of a few DDs are well defined (e.g., intellectual 
disability [ID] linked to select genetic conditions or fetal alcohol syndrome), for most DDs, 
etiology is complex and multifactorial [6–10].
Although numerous studies document associations between preterm birth (PTB) and low 
birth weight (LBW) and DDs such as CP [8,11,12], ID [12–17], autism spectrum disorder 
(ASD) [12,13,18], ADHD [12,19,20], learning disability (LD) [12,21], and general 
developmental delay [12,22,23], there is limited assessment of population impacts. Studies 
of population attributable fractions (PAFs) in US populations include an assessment of the 
Georgia Pregnancy Risk Assessment Monitoring System which estimated 42% of CP cases 
and 13% of ID cases were attributable to LBW [24], an assessment of North Dakota registry 
data which estimated 8% of ASD cases were attributable to low gestation and 8% were 
attributable to LBW [25], and an assessment of the Autism and Developmental Disabilities 
Monitoring Network which estimated 12% of ASD cases were attributable to PTB, LBW, 
and Cesarean delivery [26]. Studies from other countries of the impacts of various pregnancy 
complications and/or outcomes on ASD [27], ADHD [20], and developmental delays [28] 
reported moderate PAFs for the various perinatal factors studied. These past studies had 
notable limitations. Most did not assess the known overlap between the perinatal factors 
studied, all only assessed one or two DDs, and none assessed potential effects from co-
occurring DDs. A high proportion of children with DDs meet diagnostic criteria for multiple 
DDs [29,30]. Boulet et al. [29] reported that 43%–96% of US children with specific DD 
diagnoses had more than one DD diagnosis.
Using data from the 2011–2012 National Survey of Children’s Health (NSCH), we assessed 
associations and population impacts of PTB and LBW on subsequent DDs including CP, ID, 
ASD, ADHD, LD, behavioral or conduct problems or disorder (BCD), and other 
developmental delay. In addition to assessing a broad array of DDs side by side, we designed 
analyses to account for DD co-occurrence and examined a finer gradation of PTB and LBW 
risk than prior studies. To our knowledge, this is the largest and most comprehensive 
assessment of PAFs for DDs in a US population and the first-to-consider DD co-occurrence.
Materials and methods
Study population
The NSCH is a periodic random-digit-dial health survey of US noninstitutionalized children. 
Households are the primary sampling unit; from contacted households with children, one 
child is randomly selected. The survey is administered to a parent or guardian 
knowledgeable about the selected child’s health. The overall response rate for the 2011–
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2012 NSCH was 23% [31]. Nonresponse was more common for cell-phone numbers than 
landlines. Among contacted households with children, the interview completion rate was 
54% and 41% for landline and cell-phone calls, respectively. An empiric assessment 
indicated that sampling weight nonresponse adjustment greatly reduced the maximum 
estimated bias for key survey indicators [31].
Sample selection
From the 95,677 completed 2011–2012 NSCH interviews, we initially selected 81,590 
children 3–17 years of age. We excluded younger children because most DDs are not 
diagnosed before the age of 3 years. We additionally excluded children missing data on 
DDs, birth weight, PTB, sex, and race-ethnicity, and children with implausible birth weight-
PTB data. Our final sample size was 74,565.
Ascertainment and categorization of DDs
We assessed CP, ASD, ID, BCD, ADHD, LD, and other developmental delay. Each DD was 
ascertained using two questions: “Has a doctor or other health care provider ever told you 
that [CHILD] had [CONDITION], even if [he/she] does not have the condition now?” and 
“Does [CHILD] currently have [CONDITION]?” Verbiage for the initial LD question was 
expanded slightly to include school officials in addition to health care providers. We 
classified children as having a given DD if the parent/guardian responded affirmatively to 
both questions.
To account for DD co-occurrence, we created mutually exclusive DD outcomes. For children 
for whom more than one DD was reported, the following order of precedence was used to 
determine the mutually exclusive outcome assignment: CP-ASD-ID-BCD-ADHD-LD-other 
developmental delay. With this ordering, DDs that typically have the most pervasive 
functional impacts and most well-established associations with LBW and PTB are given 
preference [11–16,29]. ASD was given preference over ID because a previous analysis 
demonstrated that associations between PTB/LBW and ASD with ID were more comparable 
to associations for ASD only than ID only [13]. This ordering also allowed us to assess the 
“other developmental delay” category without the contributing effects of other specific 
diagnoses.
Parents who reported their child had a DD were asked to rate the severity level (mild, 
moderate, or severe). No instructions were provided about how to assign the rating. We 
categorized each DD as mild or moderate-severe. We combined moderate and severe ratings 
because of sample size constraints and empirical assessments which indicated comparability 
in the results for these two categories.
Perinatal risk factors
Respondents were asked: “What was [CHILD]’s birth weight?” and “Was [CHILD] born 
prematurely, that is, more than 3 weeks before [his/her] due date?” Response options for the 
birth weight question allowed for reporting in pounds, ounces, or grams. All data were 
converted to grams for analysis. We classified children as very LBW (VLBW)-Preterm 
(<1500 g, PTB = yes); moderately LBW (MLBW)-Preterm (1500–2499 g, PTB = yes); 
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MLBW-Term (1500–2499 g, PTB = no); normal birth weight (NBW)-Preterm (≥2500 g, 
PTB = yes); or NBW-Term (≥2500 g, PTB = no). NBW-Term served as the referent 
category. All VLBW births included in this analysis were preterm. We excluded 121 
children (0.15%) classified as both VLBW and term as implausible because birth weights 
less than 1500 g are less than the third percentile of the expected birth weight distribution at 
37 or more weeks’ gestation [32].
Potential confounders
Potential confounders were child age, sex, race-ethnicity, maternal education, and maternal 
age at child’s birth. Because for both maternal age and education, there were moderate 
numbers of missing values, we created separate “missing” categories rather than exclude 
these children.
Statistical analyses
In initial analyses, we compared distributions of potential confounders across the mutually 
exclusive DD groups and tested for general statistical differences using χ2 tests.
For core analyses, we assessed each DD two ways: as independent outcomes without 
consideration of co-occurring DDs and within the mutually exclusive categories that 
accounted for DD co-occurrence. For each DD outcome, we computed proportionate 
distributions of birth weight and gestational age and constructed logistic regression models 
to calculate adjusted relative risks (aRRs) and 95 percent confidence intervals (CIs) for 
associations with birth weight-gestational age factors. Using those data, we computed 
adjusted component PAFs which estimate population impact of each birth weight-gestational 
age factor on each DD outcome and summary PAFs which estimate the combined population 
impact of being born either LBW or PTB. CIs around PAF estimates were calculated using 
the Bonferroni inequality method [33].
In supplemental analyses, we estimated PAFs for mild versus moderate or severe DDs. 
Given the large US racial disparity in PTB [34], we also separately assessed non-Hispanic 
white (NHW) and non-Hispanic black (NHB) children. We did not examine other racial-
ethnic subgroups because of sample size constraints. Subgroup analyses were based on DD 
outcomes without consideration of co-occurring DDs.
All estimates were weighted to reflect the US noninstitutionalized population of children. 
Standard errors were adjusted to account for the complex sample design with SAS-callable 
SUDAAN 11.0.0 software (Research Triangle Institute, Research Triangle Park, NC).
Human subjects review was not required for this secondary analysis of a deidentified data 
set.
Results
Overall, 13.9% of children had one or more DD. Individual estimates ranged from 0.24% for 
CP to 8.2% for ADHD (Table 1). The percentage range for mutually exclusive DD 
categories was narrower: 0.24% for CP to 5.6% for ADHD. Overall, 49% of children with 
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DDs had greater than 1 DD and 23% had greater than 2 DDs. Thus, only 57% of children 
with ID, 34% of children with LD, and 13% of children with other developmental delay, 
were included in the respective mutually exclusive groups for these DDs.
The male-female ratio was greater than 1.0 for all groups other than CP and children without 
DDs (Table 2); the largest differential was observed for the ASD group. Children in the other 
developmental delay group were markedly younger than children without DDs, whereas 
children in all other DD groups were older. NHW race-ethnicity ranged from 44% (CP 
group) to 69% (ADHD group); maternal age at birth greater than or equal to 30 years ranged 
from 33% (BCD group) to 51% (other developmental delay group); and maternal education 
more than high school ranged from 43% (ID group) to 70% (ASD group).
Only 38% of CP cases occurred among children born NBW term compared with 69%–82% 
for other DDs and 86% for children without DDs (Table 3). The aRRs for associations 
between CP and VLBW-Preterm, MLBW-Preterm, and NBW-Preterm were 43.5, 10.1, and 
2.2, respectively. The VLBW-Preterm and MLBW-Preterm PAFs for CP were 32.0% and 
18.7%, respectively, and the PTB-LBW summary PAF for CP was 54.8%, all markedly 
higher than for any other DD.
ID, ASD, LD, and other developmental delay were also significantly associated with 
VLBW-Preterm (aRRs, 2.8–5.5), MLBW-Preterm (aRRs, 1.9–2.8), and NBW-Preterm 
(aRRs, 1.6–2.3; Table 3). Summary PAFs for these four DDs ranged from 10.2% to 19.1%. 
ADHD was modestly associated with VLBW-Preterm, MLBW-Preterm, and NBW-Preterm, 
and BCD was modestly associated with MLBW-Preterm only. The PAFs were much lower 
for these two DDs; summary PAFs for both were approximately 4%. None of the DDs were 
associated with MLBW-Term, and thus, the MLBW-Term component PAFs were all very 
low (<2%).
There were few differences in aRRs and component and summary PAFs between DDs 
assessed without consideration of co-occurrence and mutually exclusive DD outcomes 
(Table 3). CP findings were identical since CP was at the top of the mutually exclusive 
hierarchy. Findings for ASD, BCD, and ADHD were very similar for both classification 
schemes. Modest differences were observed for the other DDs. The PTB-LBW summary 
PAFs were 11% and 29% lower for the mutually exclusive LD and ID outcomes than the LD 
and ID outcomes not accounting for DD co-occurrence. Conversely, the summary PAF was 
17% higher for the mutually exclusive other developmental delay outcome. These slight 
differences in PAFs were not completely unexpected since ID, LD, and other developmental 
delay were the three DDs for which we observed the largest shifts between number with DD 
irrespective of co-occurrence and number in mutually exclusive category (Table 1).
For all DDs except BCD, summary PAFs for conditions perceived by parents as being 
moderate or severe were higher than the summary PAFs for conditions perceived as mild 
(Table 4). For ASD, ID, and LD, these differences were marked; PAFs for DDs rated as 
moderate and/or severe were 2.5 to 3.8 times higher than PAFs for DDs rated as mild.
Although estimates were imprecise, summary PAFs for all DDs were higher for NHB than 
NHW children (Table 4). For ASD, BCD, ADHD, and LD, the PAFs were 2–3 time higher 
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for NHB children; for CP and other developmental delay, the PAFs were 50% higher; and 
for ID, the PAF was 10% higher. The primary reason for these differences was a higher 
proportion of LBW and PTB, most notably VLBW-Preterm, among NHB children rather 
than differential aRRs between NHB and NHW children (data not shown).
Discussion
In this US nationally representative sample of children, PTB explained more than 50% of CP 
diagnoses, 15%–20% of ID and other developmental delay diagnoses, and 10%–15% of 
ASD and LD diagnoses. For CP, both aRRs and component PAFs showed a dose-response 
pattern: VLBW-PTBs explained substantially more CP than MLBW-PTBs, which explained 
substantially more CP than NBW-PTBs. For ASD, ID, LD, and other developmental delay, 
the VLBW-Preterm, MLBW-Preterm, and NBW-Preterm contributions were more evenly 
divided.
PTB had little impact on either ADHD or BCD prevalence; summary PAFs for both 
conditions were les than 5%. In addition, MLBW in the absence of PTB was not 
significantly associated with any DD and thus did not impact population prevalence.
All associations were independent of several sociodemographic factors. However, for all 
DDs, summary PAFs were higher for NHB than NHW children. Findings were similar 
whether we assessed each DD as an independent outcome or accounted for DD co-
occurrence. It is particularly noteworthy that our findings for LD and other developmental 
delay are not explained by the known co-occurrence of these two diagnoses with other more 
specific and typically more pervasive diagnoses—CP, ASD, and ID. Nonetheless, PAFs were 
markedly lower for most DDs rated by parents as mild versus moderate or severe.
Our findings are consistent with previous studies reporting associations between PTB and 
LBW and CP, ID, ASD, ADHD, LD, general developmental delay, and lower scores on 
standardized achievement tests [8,12–23]. In addition, as with our study, previous studies 
have reported no or modest associations between late PTB and/or moderate LBW and 
ADHD [12,20,35]. Our findings are consistent with the few previous studies assessing the 
contributions of PTB and/or LBW on CP [24], ID [24], ASD [25,26], and ADHD [20]. Here, 
we expand on those early findings by examining the full spectrum of PTB and/or LBW and 
numerous DDs and considering how DD diagnoses co-occur among children.
We examined the theoretical question of what proportion of DDs could be eliminated if we 
could eliminate PTB and LBW births. We note, however, that these perinatal factors are 
heterogeneous, representing a composite of multiple potential underlying etiologic 
mechanisms. For example, it is unknown whether the associations between DDs and PTB 
are directly causal or represent another mechanism that may be common to both DDs and 
PTB, such as maternal infection or inflammation. These PAF estimates are thus best 
interpreted as the proportion of a given DD attributable to having a suboptimal perinatal 
environment resulting in VLBW-Preterm, MLBW-Preterm, MLBW-Term, or NBW-Preterm.
Despite the many study strengths, our findings should also be considered in light of 
limitations. DD diagnoses, birth weight, and PTB were parent reported. Nonetheless, 
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previous studies suggest high reliability for parent reporting of DDs, birth weight, and 
gestational age [36–39]. In addition, our PTB and LBW rates compare well with US natality 
data from the same birth cohorts as our study population (Appendix). We lacked data on a 
child’s birth plurality and specific gestational age to further distinguish early from late PTB. 
However, we subdivided PTB into birth weight groups, known to be highly correlated with 
gestational age, particularly, VLBW [32]. Our DD severity measure, based on parent 
perception, was not well defined. Nonetheless, we observed a clear differential between DDs 
perceived as mild versus moderate-severe. Poor and/or inconsistent parent reporting would 
likely bias toward showing no difference between groups. Although we examined a 
comprehensive set of DDs, we did not include all DDs ascertained by NSCH because of 
insufficient sample sizes (e.g., Tourette’s syndrome) and vague question verbiage (e.g., 
“hearing problems” and “vision problems that cannot be corrected with standard glasses or 
contact lenses”). While we did assess the more general diagnosis of “other developmental 
delay” and examined this diagnosis in the absence of other more specific DD diagnoses, we 
do not know whether some children with other developmental delay at the time of this 
survey were subsequently identified as having more specific DDs. Nor do we know the 
specific type of “other developmental delay.” ID, ADHD, BCD, and LD are particularly 
likely to have been underdiagnosed in the youngest children (ages, 3–5 years). The survey 
response rate was low; however, sampling weights were adjusted for nonresponse. 
Moreover, our weighted estimates of PTB, LBW, and VLBW are closely aligned with those 
from US natality data (Appendix), and our estimates for two disabilities, ASD and ADHD, 
closely match independent estimates from the National Health Interview Survey [36,37]. 
Although we adjusted RRs for nonmodifiable demographic factors known to be associated 
with both PTB and DD, there was a modest level of missing values for maternal age and 
education. Nonetheless, for each DD, crude and aRRs were very similar (data not shown) 
indicating little confounding. Finally, PAF estimates are subject to imprecision; for example, 
the PAF and corresponding CI for ASD were 11.9% (5.6%–19.4%).
Beyond specific study limitations, PAF estimates should be interpreted in the context of 
potential limitations of the methodology generally including possible competing risks, 
survival time effects, censoring, and causality assumptions [40]. As described, a strength of 
our study is that we sought a priori to minimize these limitations. Because DDs commonly 
co-occur, and in some children not all individual, DDs are completely disentangled and 
diagnosed (i.e., diagnosis of one DD might be a “competing risk” for a second DD 
diagnosis), we analyzed multiple DDs side by side and assessed PAFs for each DD with and 
without consideration of co-occurring DDs. Given that the vast majority of our study 
population was 6 years or older, “survivorship” issues were minimized as most children had 
reached an age where nearly all DDs could be recognized. Still, we included children of 3–5 
years in our study population because some DDs are diagnosed by age 3 years; this might 
have attenuated some estimates. Conversely, if children born VLBW were monitored more 
closely for DDs and diagnosed earlier than children born NBW term, this could have slightly 
inflated some PAF estimates, particularly for DDs with milder functional impacts. Although 
there is likely censoring of our outcomes due to fetal, infant, and early child death, this is a 
global problem for any analysis of DDs; even if the data source included fetal deaths, it 
would be problematic to count them in the denominator when they had no chance of being 
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included in the numerator. Finally, while PAF estimates assume a causal relationship 
between PTB and/or LBW and the fetal environments that bring about these adverse birth 
outcomes, we do not know of interventions to prevent the vast share of PTB and/or LBW. 
Nonetheless, PAF estimates provide valuable insight into population impacts.
Conclusion
Despite recent declines, PTB remains common; 11.6% of US births in 2012 were preterm 
and 3.4% were very preterm (<37 and <34-week gestation, respectively) [34]. This study 
demonstrates the sizable contribution of PTB on child neurodevelopment. Efforts to control 
PTB are complex. Moreover, while our findings are informative on a population level, they 
do not indicate which PTB etiologic subgroups most contribute to the associations between 
PTB and DDs. Nonetheless, these findings highlight the need to minimize modifiable risk 
factors for PTB through comprehensive health care for women before and during their 
pregnancies.
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Appendix
Comparison of NSCH Study sample with US population data on adverse perinatal outcome 
for same birth cohorts*
Perinatal
outcome
US natality data from published
reports
Current NSCH
study sample (birth
cohorts include
1994 to 2008)
1994 1998 2001 2004 2006 2008 Total study
sample
(weighted),
n = 74,565
Sample limited
to children
without DDs
(weighted),
n = 64,478
% PTB 11.0 11.6 11.9 12.5 12.8 12.3 11.5 10.5
% LBW   7.3   7.6   7.7   8.1   8.3   8.2   9.3   7.5
% VLBW   1.0   1.5   1.4   1.5   1.5   1.5   1.5   1.2
*
There are some known differences in populations represented by NSCH and birth cohorts. NSCH data do not represent US 
children who died or migrated out of the country shortly after birth. Conversely, US birth cohort natality data do not include 
children who were born outside the United States and subsequently migrated into the United States.
Schieve et al. Page 11
Ann Epidemiol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Schieve et al. Page 12
Ta
bl
e 
1
D
ev
el
op
m
en
ta
l d
isa
bi
lit
y 
cl
as
sif
ic
at
io
n 
sc
he
m
es
 a
nd
 sa
m
pl
e 
siz
es
: c
hi
ld
re
n 
3–
17
 y
ea
rs
 o
f a
ge
, 2
01
1–
20
12
 N
at
io
na
l S
ur
ve
y 
of
 C
hi
ld
re
n’
s H
ea
lth
D
ev
el
op
m
en
ta
l
D
isa
bi
lit
y 
(w
ith
ou
t
co
n
sid
er
at
io
n 
of
co
-o
cc
u
rr
en
ce
)
To
ta
l N
o.
 w
ith
di
ag
no
sis
%
M
ut
ua
lly
 e
xc
lu
siv
e 
D
D
 c
at
eg
or
ie
s
To
ta
l N
o.
 in
 m
ut
ua
lly
ex
cl
us
iv
e 
ca
te
go
ry
%
%
 o
f t
ot
al
 w
ith
di
ag
no
sis
 in
cl
ud
ed
in
 m
ut
ua
lly
ex
cl
us
iv
e 
ca
te
go
ry
CP
23
6
0.
2
CP
23
6
0.
2
10
0.
0
A
SD
14
47
1.
9
A
SD
 (n
o C
P)
14
16
1.
9
97
.9
ID
86
2
1.
1
ID
 (n
o C
P, 
A
SD
)
49
2
0.
6
57
.1
B
CD
19
84
3.
1
B
CD
 (n
o C
P, 
A
SD
, I
D
)
14
46
2.
3
72
.9
A
D
H
D
59
62
8.
2
A
D
H
D
 (n
o C
P, 
A
SD
, I
D
, B
CD
)
41
98
5.
6
70
.4
LD
56
03
7.
8
LD
 (n
o C
P, 
A
SD
, I
D
, B
CD
, A
D
H
D
)
19
53
2.
9
34
.9
O
th
er
 d
ev
el
op
m
en
ta
l d
el
ay
26
08
3.
4
O
th
er
 d
ev
el
op
m
en
ta
l d
el
ay
 (n
o C
P,
A
SD
, I
D
, B
CD
, A
D
H
D
, L
D
)
34
6
0.
4
13
.3
N
o 
de
v
el
op
m
en
ta
l d
el
ay
64
,4
78
86
.2
N
o 
de
v
el
op
m
en
ta
l d
el
ay
64
,4
78
86
.2
—
Ann Epidemiol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Schieve et al. Page 13
Ta
bl
e 
2
Pe
rc
en
ta
ge
 d
ist
rib
u
tio
ns
*
 
o
f s
oc
io
de
m
og
ra
ph
ic
 c
ha
ra
ct
er
ist
ic
s b
y 
de
v
el
op
m
en
ta
l d
isa
bi
lit
y 
ca
te
go
ry
: c
hi
ld
re
n 
3–
17
 y
ea
rs
 o
f a
ge
, 2
01
1–
20
12
 N
at
io
na
l 
Su
rv
ey
 o
f C
hi
ld
re
n’
s H
ea
lth
C
ha
ra
ct
er
ist
ic
D
D
 g
ro
u
p—
m
ut
ua
lly
 e
xc
lu
siv
e 
ca
te
go
ri
es
P
C
P,
 n
 
=
 2
36
A
SD
, n
 
=
 1
41
6
ID
, n
 
=
 4
92
BC
D
, n
 
=
 1
44
6
A
D
H
D
, n
 
=
 4
19
8
LD
, n
 
=
 1
95
3
O
th
er
, 
n
 
=
 3
46
N
on
e, 
n
 
=
 6
44
78
Ch
ild
 se
x
 
 
M
al
e
41
.0
82
.9
59
.3
68
.2
67
.6
53
.2
61
.1
48
.7
<
.0
1
 
 
Fe
m
al
e
59
.0
17
.1
40
.7
31
.8
32
.4
46
.8
38
.9
51
.3
Ch
ild
 a
ge
 (y
)
 
 
3–
5
17
.4
15
.9
10
.6
9.
2
3.
8
8.
0
49
.1
22
.3
<
.0
1
 
 
6–
11
35
.0
45
.5
39
.2
45
.3
41
.7
40
.7
43
.5
39
.0
 
 
12
–1
7
47
.7
38
.7
50
.2
45
.5
54
.6
51
.4
7.
5
38
.7
Ch
ild
 ra
ce
-e
th
ni
ci
ty
 
 
N
on
-H
isp
an
ic
 w
hi
te
44
.4
60
.6
59
.3
47
.5
69
.2
49
.5
60
.1
53
.5
<
.0
1
 
 
N
on
-H
isp
an
ic
 b
la
ck
25
.6
11
.1
20
.6
21
.6
12
.6
15
.3
9.
5
13
.6
 
 
H
isp
an
ic
18
.9
19
.6
11
.4
21
.2
11
.3
26
.4
22
.0
22
.9
 
 
O
th
er
11
.1
8.
7
8.
7
9.
7
6.
9
8.
8
8.
4
10
.0
M
at
er
na
l a
ge
 a
t b
irt
h 
(y)
 
 
12
–1
9
8.
0
4.
1
7.
3
11
.6
9.
4
9.
5
3.
3
6.
4
<
.0
1
 
 
20
–2
9
41
.2
43
.2
37
.1
43
.9
44
.7
44
.6
41
.2
43
.9
 
 
30
–3
9
31
.7
40
.0
36
.1
27
.2
33
.6
33
.1
43
.7
39
.1
 
 
40
+
7.
6
6.
1
6.
6
5.
5
3.
9
5.
1
6.
9
3.
9
 
 
M
iss
in
g
11
.5
6.
6
13
.0
11
.8
8.
4
7.
7
4.
9
6.
8
M
at
er
na
l e
du
ca
tio
n 
at
 ti
m
e 
of
 su
rv
ey
 
 
<
H
ig
h 
sc
ho
ol
14
.5
8.
6
19
.0
15
.9
9.
5
17
.8
10
.6
12
.8
<
.0
1
 
 
H
ig
h 
sc
ho
ol
24
.8
14
.5
21
.0
27
.8
22
.1
27
.1
23
.3
19
.7
 
 
>
H
ig
h 
sc
ho
ol
50
.2
70
.5
42
.7
44
.1
60
.3
47
.3
63
.2
61
.3
 
 
M
iss
in
g
10
.5
6.
5
17
.3
12
.2
8.
1
7.
8
2.
9
6.
2
*
A
ll 
es
tim
at
es
 w
er
e 
w
ei
gh
te
d 
to
 re
fle
ct
 th
e 
U
S 
no
ni
ns
tit
ut
io
na
liz
ed
 p
op
ul
at
io
n 
of
 c
hi
ld
re
n.
Ann Epidemiol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Schieve et al. Page 14
Ta
bl
e 
3
R
el
at
iv
e 
ris
ks
 a
nd
 c
om
po
ne
nt
 a
nd
 su
m
m
ar
y 
po
pu
la
tio
n 
at
tri
bu
ta
bl
e 
fra
ct
io
ns
 fo
r a
ss
oc
ia
tio
ns
 b
et
w
ee
n 
ad
ve
rs
e 
pe
rin
at
al
 o
ut
co
m
es
 a
nd
 d
ev
el
op
m
en
ta
l 
di
sa
bi
lit
ie
s: 
ch
ild
re
n 
3–
17
 y
ea
rs
 o
f a
ge
, 2
01
1–
20
12
 N
at
io
na
l S
ur
ve
y 
of
 C
hi
ld
re
n’
s H
ea
lth
A
ss
es
sm
en
t o
f D
D
s w
ith
ou
t c
on
sid
er
at
io
n 
of
 c
o-
oc
cu
rr
en
ce
A
ss
es
sm
en
t o
f D
D
s i
n 
m
ut
ua
lly
 e
xc
lu
siv
e 
ca
te
go
ri
es
.
Bi
rt
h 
w
ei
gh
t-g
es
ta
tio
na
l
a
ge
 g
ro
u
p
%
 C
as
es
*
a
R
R
 (9
5%
 C
I)†
PA
F 
(95
%
 C
I)‡
Bi
rt
h 
w
ei
gh
t-g
es
ta
tio
na
l
a
ge
 g
ro
u
p
%
 C
as
es
a
R
R
 (9
5%
 C
I)
PA
F 
(95
%
 C
I)
CP
CP
 
 
V
LB
W
-
Pr
et
er
m
§
32
.7
43
.5
 (2
4.4
, 7
7.6
)
32
.0
 (2
0.3
, 4
6.2
)
V
LB
W
-
Pr
et
er
m
32
.7
43
.5
 (2
4.4
, 7
7.6
)
32
.0
 (2
0.3
, 4
6.2
)
 
 
M
LB
W
-
Pr
et
er
m
20
.7
10
.1
 (5
.0,
 20
.7)
18
.7
 (8
.7,
 33
.6)
M
LB
W
-
Pr
et
er
m
20
.7
10
.1
 (5
.0,
 20
.7)
18
.7
 (8
.7,
 33
.6)
 
 
M
LB
W
-
Te
rm
2.
9
1.
7 
(0.
7, 
4.4
)
1.
2 
(0.
0, 
5.9
)
M
LB
W
-
Te
rm
2.
9
1.
7 
(0.
7, 
4.4
)
1.
2 
(0.
0, 
5.9
)
 
 
N
BW
-
Pr
et
er
m
5.
4
2.
2 
(1.
04
, 4
.6)
2.
9 
(0.
0, 
8.8
)
N
BW
-
Pr
et
er
m
5.
4
2.
2 
(1.
04
, 4
.6)
2.
9 
(0.
0, 
8.8
)
 
 
N
BW
-
Te
rm
38
.3
1.
0
0.
0
N
BW
-
Te
rm
38
.3
1.
0
0.
0
 
 
Su
m
m
ar
y 
PA
F
—
—
54
.8
 (3
8.3
, 6
8.9
)
Su
m
m
ar
y 
PA
F
—
—
54
.8
 (3
8.3
, 6
8.9
)
A
SD
A
SD
 (n
o C
P)
 
 
V
LB
W
-
Pr
et
er
m
4.
2
3.
7 
(1.
8, 
7.7
)
3.
1 
(0.
7, 
8.8
)
V
LB
W
-
Pr
et
er
m
3.
9
3.
6 
(1.
6, 
7.9
)
2.
8 
(0.
5, 
8.8
)
 
 
M
LB
W
-
Pr
et
er
m
6.
8
1.
9 
(1.
3, 
2.7
)
3.
1 
(0.
8, 
6.5
)
M
LB
W
-
Pr
et
er
m
6.
7
1.
9 
(1.
3, 
2.7
)
3.
1 
(0.
8, 
6.5
)
 
 
M
LB
W
-
Te
rm
2.
7
1.
2 
(0.
6, 
2.1
)
0.
4 
(0.
0, 
3.0
)
M
LB
W
-
Te
rm
2.
7
1.
2 
(0.
6, 
2.2
)
0.
4 
(0.
0, 
3.0
)
 
 
N
BW
-
Pr
et
er
m
10
.7
2.
0 
(1.
3, 
3.0
)
5.
3 
(1.
3, 
11
.2)
N
BW
-
Pr
et
er
m
10
.6
2.
0 
(1.
3, 
3.0
)
5.
3 
(1.
2, 
11
.2)
 
 
N
BW
-
Te
rm
75
.7
1.
0
0.
0
N
BW
-
Te
rm
76
.1
1.
0
0.
0
 
 
Su
m
m
ar
y 
PA
F
—
—
11
.9
 (5
.6,
 19
.4)
Su
m
m
ar
y 
PA
F
—
—
11
.6
 (5
.3,
 19
.2)
ID
ID
 (n
o C
P, 
A
SD
)
 
 
V
LB
W
-
Pr
et
er
m
6.
6
5.
1 
(2.
6, 
10
.0)
5.
3 
(1.
7, 
13
.0)
V
LB
W
-
Pr
et
er
m
3.
3
2.
6 
(1.
1, 
6.1
)
2.
0 
(0.
0, 
6.7
)
 
 
M
LB
W
-
Pr
et
er
m
9.
6
2.
7 
(1.
8, 
4.2
)
6.
1 
(2.
5, 
11
.3)
M
LB
W
-
Pr
et
er
m
8.
9
2.
4 
(1.
4, 
4.2
)
5.
2 
(1.
0, 
12
.2)
 
 
M
LB
W
-
Te
rm
4.
6
1.
7 
(0.
9, 
2.9
)
1.
8 
(0.
0, 
5.7
)
M
LB
W
-
Te
rm
5.
0
1.
7 
(0.
9, 
3.1
)
2.
0 
(0.
0, 
6.6
)
 
 
N
BW
-
Pr
et
er
m
10
.0
2.
2 
(1.
5, 
3.2
)
5.
4 
(1.
9, 
10
.1)
N
BW
-
Pr
et
er
m
8.
8
1.
9 
(1.
2, 
3.0
)
4.
0 
(0.
4, 
9.5
)
 
 
N
BW
-
Te
rm
69
.2
1.
0
0.
0
N
BW
-
Te
rm
74
.0
1.
0
0.
0
 
 
Su
m
m
ar
y 
PA
F
—
—
18
.6
 (1
0.6
, 2
7.8
)
Su
m
m
ar
y 
PA
F
—
—
13
.2
 (4
.9,
 23
.4)
B
CD
B
CD
 (n
o C
P, 
A
SD
, I
D
)
 
 
V
LB
W
-
Pr
et
er
m
1.
8
1.
1 
(0.
6, 
2.0
)
0.
2 
(0.
0, 
1.8
)
V
LB
W
-
Pr
et
er
m
1.
8
1.
2 
(0.
6, 
2.6
)
0.
3 
(0.
0, 
2.6
)
 
 
M
LB
W
-
Pr
et
er
m
6.
3
1.
5 
(1.
1, 
2.1
)
2.
1 
(0.
1, 
4.8
)
M
LB
W
-
Pr
et
er
m
6.
5
1.
6 
(1.
1, 
2.2
)
2.
3 
(0.
1, 
5.5
)
 
 
M
LB
W
-
Te
rm
3.
4
1.
0 
(0.
7, 
1.6
)
0.
1 
(0.
0, 
2.2
)
M
LB
W
-
Te
rm
3.
8
1.
1 
(0.
7, 
1.8
)
0.
4 
(0.
0, 
3.1
)
Ann Epidemiol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Schieve et al. Page 15
A
ss
es
sm
en
t o
f D
D
s w
ith
ou
t c
on
sid
er
at
io
n 
of
 c
o-
oc
cu
rr
en
ce
A
ss
es
sm
en
t o
f D
D
s i
n 
m
ut
ua
lly
 e
xc
lu
siv
e 
ca
te
go
ri
es
.
Bi
rt
h 
w
ei
gh
t-g
es
ta
tio
na
l
a
ge
 g
ro
u
p
%
 C
as
es
*
a
R
R
 (9
5%
 C
I)†
PA
F 
(95
%
 C
I)‡
Bi
rt
h 
w
ei
gh
t-g
es
ta
tio
na
l
a
ge
 g
ro
u
p
%
 C
as
es
a
R
R
 (9
5%
 C
I)
PA
F 
(95
%
 C
I)
 
 
N
BW
-
Pr
et
er
m
7.
4
1.
4 
(0.
99
, 1
.9)
1.
9 
(0.
0, 
5.0
)
N
BW
-
Pr
et
er
m
7.
2
1.
4 
(0.
9, 
2.0
)
1.
9 
(0.
0, 
5.8
)
 
 
N
BW
-
Te
rm
81
.2
1.
0
0.
0
N
BW
-
Te
rm
80
.8
1.
0
0.
0
 
 
Su
m
m
ar
y 
PA
F
—
—
4.
3 
(0.
3, 
9.0
)
Su
m
m
ar
y 
PA
F
—
—
5.
0 
(0.
3, 
10
.5)
A
D
H
D
A
D
H
D
 (n
o C
P, 
A
SD
, I
D
, B
CD
)
 
 
V
LB
W
-
Pr
et
er
m
2.
2
1.
6 
(1.
2, 
2.3
)
0.
9 
(0.
2, 
1.9
)
V
LB
W
-
Pr
et
er
m
1.
6
1.
3 
(0.
9, 
2.0
)
0.
4 
(0.
0, 
1.3
)
 
 
M
LB
W
-
Pr
et
er
m
5.
0
1.
3 
(1.
04
, 1
.5)
1.
1 
(0.
1, 
2.3
)
M
LB
W
-
Pr
et
er
m
4.
7
1.
3 
(0.
99
, 1
.6)
1.
0 
(0.
0, 
2.5
)
 
 
M
LB
W
-
Te
rm
2.
8
1.
0 
(0.
8, 
1.3
)
0.
0 
(0.
0, 
1.0
)
M
LB
W
-
Te
rm
2.
6
0.
9 
(0.
7, 
1.3
)
0.
0 
(0.
0, 
1.1
)
 
 
N
BW
-
Pr
et
er
m
8.
2
1.
5 
(1.
2, 
1.8
)
2.
5 
(1.
0, 
4.5
)
N
BW
-
Pr
et
er
m
8.
1
1.
5 
(1.
2, 
1.9
)
2.
6 
(0.
6, 
5.1
)
 
 
N
BW
-
Te
rm
81
.8
1.
0
0.
0
N
BW
-
Te
rm
83
.0
1.
0
0.
0
 
 
Su
m
m
ar
y 
PA
F
—
—
4.
4 
(2.
0, 
7.1
)
Su
m
m
ar
y 
PA
F
—
—
3.
8 
(1.
0, 
7.0
6)
LD
LD
 (n
o C
P, 
A
SD
, I
D
, B
CD
, A
D
H
D
)
 
 
V
LB
W
-
Pr
et
er
m
3.
7
2.
8 
(2.
1, 
3.7
)
2.
4 
(1.
3, 
3.8
)
V
LB
W
-
Pr
et
er
m
4.
2
3.
3 
(2.
0, 
5.4
)
3.
0 
(1.
2, 
5.9
)
 
 
M
LB
W
-
Pr
et
er
m
7.
8
2.
0 
(1.
7, 
2.4
)
3.
9 
(2.
4, 
5.7
)
M
LB
W
-
Pr
et
er
m
7.
1
2.
0 
(1.
3, 
2.8
)
3.
5 
(1.
0, 
7.0
)
 
 
M
LB
W
-
Te
rm
3.
6
1.
2 
(0.
9, 
1.6
)
0.
7 
(0.
0, 
2.0
)
M
LB
W
-
Te
rm
4.
2
1.
3 
(0.
8, 
2.0
)
1.
0 
(0.
0, 
3.8
)
 
 
N
BW
-
Pr
et
er
m
8.
3
1.
6 
(1.
4, 
2.0
)
3.
2 
(1.
6, 
5.2
)
N
BW
-
Pr
et
er
m
6.
5
1.
4 
(1.
00
, 1
.9)
1.
7 
(0.
0, 
4.4
)
 
 
N
BW
-
Te
rm
76
.5
1.
0
0.
0
N
BW
-
Te
rm
77
.9
1.
0
0.
0
 
 
Su
m
m
ar
y 
PA
F
—
—
10
.2
 (7
.3,
 13
.4)
Su
m
m
ar
y 
PA
F
—
—
9.
1 
(4.
4, 
14
.5)
O
th
er
 d
ev
el
op
m
en
ta
l d
el
ay
O
th
er
 d
ev
el
op
m
en
ta
l d
el
ay
 (n
o C
P, 
A
SD
, I
D
, B
CD
, A
D
H
D
, L
D
)
 
 
V
LB
W
-
Pr
et
er
m
6.
8
5.
5 
(4.
1, 
7.4
)
5.
6 
(3.
6, 
8.2
)
V
LB
W
-
Pr
et
er
m
8.
8
9.
8 
(5.
0, 
19
.2)
7.
9 
(3.
6, 
15
.4)
 
 
M
LB
W
-
Pr
et
er
m
10
.1
2.
8 
(2.
2, 
3.6
)
6.
5 
(4.
0, 
9.6
)
M
LB
W
-
Pr
et
er
m
9.
0
2.
7 
(1.
4, 
5.1
)
5.
6 
(1.
0, 
14
.0)
 
 
M
LB
W
-
Te
rm
3.
5
1.
4 
(0.
9, 
2.0
)
1.
0 
(0.
0, 
2.9
)
M
LB
W
-
Te
rm
2.
6
1.
1 
(0.
4, 
3.5
)
0.
3 
(0.
0, 
6.2
)
 
 
N
BW
-
Pr
et
er
m
10
.7
2.
3 
(1.
8, 
3.0
)
6.
1 
(3.
2, 
9.8
)
N
BW
-
Pr
et
er
m
12
.9
3.
0 
(1.
6, 
5.6
)
8.
6 
(2.
2, 
19
.5)
 
 
N
BW
-
Te
rm
68
.8
1.
0
0.
0
N
BW
-
Te
rm
66
.8
1.
0
0.
0
 
 
Su
m
m
ar
y 
PA
F
—
—
19
.1
 (1
4.2
, 2
4.2
)
Su
m
m
ar
y 
PA
F
—
—
22
.4
 (1
0.9
, 3
6.0
)
*
%
 c
as
es
: (
nu
mb
er 
of 
ex
po
se
d 
ca
se
s/n
um
be
r o
f a
ll 
ca
se
s) 
× 1
00
, w
eig
hte
d.
† a
R
R
: R
el
at
iv
e 
ris
k,
 a
dju
ste
d f
or 
ch
ild
 ag
e, 
sex
, 
ra
ce
/e
th
ni
ci
ty
,
 
m
at
er
na
l e
du
ca
tio
n,
 a
nd
 m
at
er
na
l a
ge
. F
in
di
ng
s i
n 
bo
ld
fa
ce
 in
di
ca
te
 9
5%
 co
nf
id
en
ce
 in
te
rv
al
 ex
cl
ud
es
 1
.0
.
‡ P
A
F 
es
tim
at
e 
or
 lo
w
er
 b
ou
nd
 o
f P
A
F 
CI
 re
po
rte
d 
as
 0
.0
 fo
r a
ll 
in
sta
nc
es
 in
 w
hi
ch
 th
e 
va
lu
e 
w
as
 le
ss
 th
an
 0
.0
. F
in
di
ng
s i
n 
bo
ld
fa
ce
 in
di
ca
te
 9
5%
 co
nf
id
en
ce
 in
te
rv
al
 ex
cl
ud
es
 0
.0
.
Ann Epidemiol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Schieve et al. Page 16
§ A
ll 
V
LB
W
 b
irt
hs
 w
er
e 
pr
et
er
m
. W
e 
ex
cl
ud
ed
 fr
om
 o
ur
 st
ud
y 
sa
m
pl
e 
a 
sm
al
l n
um
be
r o
f c
hi
ld
re
n 
cl
as
sif
ie
d 
as
 b
ot
h 
V
LB
W
 a
nd
 T
er
m
. 
Th
es
e 
da
ta
 w
er
e 
co
ns
id
er
ed
 im
pl
au
sib
le
 a
s b
irt
h 
w
ei
gh
ts 
le
ss
 th
an
 
15
00
 g
 ar
e b
el
ow
 th
e 
th
ird
 p
er
ce
nt
ile
 o
f w
ha
t i
s e
x
pe
ct
ed
 fo
r b
irt
hs
 a
t 3
7 
w
ee
ks
’ g
es
ta
tio
n 
or
 h
ig
he
r b
as
ed
 o
n 
a 
U
S 
na
tio
na
l r
ef
er
en
ce
 fo
r b
ot
h 
m
al
es
 a
nd
 fe
m
al
es
.
Ann Epidemiol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Schieve et al. Page 17
Table 4
Summary population attributable fractions for impact of preterm and low birth weight on developmental 
disabilities among subgroups based on parent-reported disability severity level and child race-ethnicity: 
children 3–17 years of age, 2011–2012 National Survey of Children’s Health
DD type (without
consideration of DD co-
occurrence)
Severity reported
as mild PAF (95% 
CI)*
Severity reported as 
moderate
or severe PAF (95% 
CI)
Non-Hispanic
white PAF (95% CI)*
Non-Hispanic black 
PAF (95% CI)
CP 48.0 (26.4, 68.0) 62.7 (39.4, 80.1) 46.1 (28.2, 63.2) 68.5 (27.5, 90.6)
ASD 5.2 (0.0, 13.0) 19.5 (8.7, 32.8) 6.8 (1.3, 13.6) 16.5 (0.0, 43.5)
ID 6.9 (0.0, 22.2) 17.7 (6.6, 31.4) 16.3 (8.2, 26.0) 17.8 (2.0, 39.0)
BCD 5.5 (0.0, 17.1) 4.7 (0.0, 11.0) 4.1 (0.0, 10.9) 11.9 (0.7, 26.0)
ADHD 3.0 (0.0, 7.1) 4.9 (0.3, 10.4) 3.6 (0.9, 6.7) 10.0 (2.0, 19.5)
LD 5.3 (0.5, 11.3) 16.2 (7.1, 27.0) 8.0 (4.9, 11.6) 15.9 (7.9, 25.2)
Other developmental delay 21.0 (8.9, 35.9) 28.0 (3.2, 57.7) 15.9 (10.6, 21.7) 23.1 (10.3, 37.6)
*
PAF estimate or lower bound of PAF CI reported as 0.0 for all instances in which the value was less than 0.0. Findings in boldface indicate 95% 
confidence interval excludes 0.0.
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